Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 20Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Brain Neoplasms 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1

Interventions

lenvatinib 2Temozolomide 2temsirolimus 1cabozantinib 1anlotinib 1Vorinostat 1Vinorelbine 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Paraganglioma, Extra-Adrenal × cabozantinib × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡